Skip to main content

Medication Nonadherence in Parkinson’s Disease

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21:793–811.

    PubMed  Article  Google Scholar 

  2. 2.

    Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.

    PubMed  Google Scholar 

  3. 3.

    Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med. 2001;77:703–7.

    Article  CAS  Google Scholar 

  4. 4.

    Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841–5.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542–5.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020–4.

    PubMed  Article  Google Scholar 

  7. 7.

    Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119–22.

    PubMed  CAS  Google Scholar 

  8. 8.

    Ose D, Mahler C, Vogel I, Ludt S, Szecsenyi J, Freund T. Let’s talk about medication: concordance in rating medication adherence among multimorbid patients and their general practitioners. Patient Prefer Adherence. 2012;6:839–45.

    PubMed  Article  Google Scholar 

  9. 9.

    Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson’s disease. Mov Disord. 2008;23:359–65.

    PubMed  Article  Google Scholar 

  10. 10.

    Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: Evidence from administrative claims data. Mov Disord. 2010;25:474–80.

    PubMed  Article  Google Scholar 

  11. 11.

    Grosset KA, Bone I, Reid JL, Grosset D. Measuring therapy adherence in Parkinson’s disease: a comparison of methods. J Neurol Neurosurg Psychiatry. 2006;77:249–51.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol. 2007;7:20.

    PubMed  Article  Google Scholar 

  13. 13.

    Leoni O, Martignoni E, Cosentino M, et al. Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf. 2002;11:149–57.

    PubMed  Article  Google Scholar 

  14. 14.

    Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov Disord. 2005;20:1397–404.

    PubMed  Article  Google Scholar 

  15. 15.

    Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20:1502–7.

    PubMed  Article  Google Scholar 

  16. 16.

    Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.

    PubMed  Google Scholar 

  17. 17.

    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24:2175–86.

    PubMed  Article  Google Scholar 

  19. 19.

    Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25:2493–500.

    PubMed  Article  Google Scholar 

  20. 20.

    Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008;64 Suppl 2:S81–92.

    PubMed  Google Scholar 

  21. 21.

    Insel K, Morrow D, Brewer B, Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci. 2006;61:P102–7.

    PubMed  Article  Google Scholar 

  22. 22.

    Stoehr GP, Lu SY, Lavery L, et al. Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. Am J Geriatr Pharmacother. 2008;6:255–63.

    PubMed  Article  Google Scholar 

  23. 23.

    Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med. 2006;21:1215–21.

    PubMed  Article  Google Scholar 

  24. 24.

    Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9:11–23.

    PubMed  Article  Google Scholar 

  25. 25.

    Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24:826–32.

    PubMed  Article  Google Scholar 

  26. 26.

    Daley DJ, Deane KH, Gray RJ, et al. The use of carer assisted adherence therapy for people with Parkinson’s disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials. 2011;12:251.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging. 2009;26:145–55.

    PubMed  Article  Google Scholar 

  28. 28.

    Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012;25:433–47.

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Valldeoriola F, Coronell C, Pont C, et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study. Eur J Neurol. 2011;18:980–7.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord. 2004;19:513–7.

    PubMed  Article  Google Scholar 

Download references

Acknowledgment

Jori E. Fleisher has received training grant support from the NIH (T32-NS-061779).

Compliance with Ethics Guidelines

Conflict of Interest

Jori E. Fleisher and Matthew B. Stern declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jori E. Fleisher.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fleisher, J.E., Stern, M.B. Medication Nonadherence in Parkinson’s Disease. Curr Neurol Neurosci Rep 13, 382 (2013). https://doi.org/10.1007/s11910-013-0382-z

Download citation

Keywords

  • Parkinson’s disease
  • Therapeutics
  • Adherence
  • Patient education
  • Health services
  • Medication nonadherence